- Home
- TCRT vs HSCS Comparison
TCRT vs HSCS Comparison
Compare TCRT & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRT
- HSCS
- Stock Information
- Founded
- TCRT 1998
- HSCS 2007
- Country
- TCRT United States
- HSCS United States
- Employees
- TCRT N/A
- HSCS N/A
- Industry
- TCRT Biotechnology: Pharmaceutical Preparations
- HSCS Medical Specialities
- Sector
- TCRT Health Care
- HSCS Health Care
- Exchange
- TCRT Nasdaq
- HSCS Nasdaq
- Market Cap
- TCRT 3.9M
- HSCS 3.7M
- IPO Year
- TCRT N/A
- HSCS 2022
- Fundamental
- Price
- TCRT $1.77
- HSCS $3.65
- Analyst Decision
- TCRT
- HSCS Strong Buy
- Analyst Count
- TCRT 0
- HSCS 2
- Target Price
- TCRT N/A
- HSCS $13.00
- AVG Volume (30 Days)
- TCRT 308.7K
- HSCS 119.8K
- Earning Date
- TCRT 08-14-2025
- HSCS 09-11-2025
- Dividend Yield
- TCRT N/A
- HSCS N/A
- EPS Growth
- TCRT N/A
- HSCS N/A
- EPS
- TCRT N/A
- HSCS N/A
- Revenue
- TCRT $6,000.00
- HSCS $4,350.00
- Revenue This Year
- TCRT $5,680,500.00
- HSCS $21,003.45
- Revenue Next Year
- TCRT N/A
- HSCS $533.33
- P/E Ratio
- TCRT N/A
- HSCS N/A
- Revenue Growth
- TCRT N/A
- HSCS N/A
- 52 Week Low
- TCRT $1.31
- HSCS $2.36
- 52 Week High
- TCRT $6.20
- HSCS $6.47
- Technical
- Relative Strength Index (RSI)
- TCRT 24.52
- HSCS 50.13
- Support Level
- TCRT $2.23
- HSCS $3.25
- Resistance Level
- TCRT $2.44
- HSCS $3.93
- Average True Range (ATR)
- TCRT 0.34
- HSCS 0.32
- MACD
- TCRT -0.04
- HSCS 0.04
- Stochastic Oscillator
- TCRT 6.76
- HSCS 65.85
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.